US2015320700A1PendingUtilityA1

Geranium oil and constituents thereof for treatment of neurodegenerative diseases

35
Assignee: ISRAEL STATEPriority: May 7, 2012Filed: May 7, 2013Published: Nov 12, 2015
Est. expiryMay 7, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Anat ElmannUzi Ravid
A61P 25/16A23L 27/12A61K 31/045A61K 31/122A61P 25/28A23V 2002/00A23L 33/115A23L 33/105A61K 36/185A23L 1/3002
35
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the use of effective amount of Pelargonium graveolens essential oil or extract or constituents thereof selected from a group consisting of: (S)(−)citronellol, linalool, menthone and isomenthone or any combination thereof, in the preparation of a medicament for treating a mammal suffering from or susceptible to a neurodegenerative condition which can be improved or prevented by inhibition of acetylcholinesterase (ACliE).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . The use of effective amount of any one of the  Pelargonium graveolens  constituents selected from a group consisting of: (S)(−)citronellol, linalool, menthone and isomenthone or any combination thereof, in the preparation of a medicament for treating a mammal suffering from or susceptible to a neurodegenerative condition which can be improved or prevented by inhibition of acetylcholinesterase (AChE). 
     
     
         2 . The use of  claim 1 , wherein (S)(−)citronellol is the sole active ingredient. 
     
     
         3 . The use of  claim 1 , wherein linalool is the sole active ingredient. 
     
     
         4 . The use of  claim 1 , wherein menthone is the sole active ingredient. 
     
     
         5 . The use of  claim 1 , wherein isomenthone is the sole active ingredient. 
     
     
         6 . The use according to  claim 1 , wherein the  Pelargonium graveolens  constituents are in the form of essential oil. 
     
     
         7 . The use according to  claim 1 , wherein said neurodegenerative condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, parkinsonian dementia (PDem), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), anorexia nervosa, traumatic brain injury (TBI), and Parkinson's disease falling short of dementia (CIND-PD). 
     
     
         8 . An effective amount of any one of  Pelargonium graveolens  constituents selected from a group consisting of: (S)(−)citronellol, linalool, menthone and isomenthone or any combination thereof, for use in treating a mammal suffering from or susceptible to a neurodegenerative condition which can be improved or prevented by inhibition of acetylcholinesterase (AChE). 
     
     
         9 . The  Pelargonium graveolens  constituents of  claim 8 , wherein (S)(−) citronellol is the sole active ingredient. 
     
     
         10 . The  Pelargonium graveolens  constituents of  claim 8 , wherein linalool is the sole active ingredient. 
     
     
         11 . The  Pelargonium graveolens  constituents of  claim 8 , wherein menthone is the sole active ingredient. 
     
     
         12 . The  Pelargonium graveolens  constituents of  claim 8 , wherein isomenthone is the sole active ingredient. 
     
     
         13 . The  Pelargonium graveolens  constituents according to  claim 8 , wherein said neurodegenerative condition is selected from the group consisting of Parkinson's disease, parkinsonian dementia (PDem), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), anorexia nervosa, traumatic brain injury (TBI), and Parkinson's disease falling short of dementia (CIND-PD). 
     
     
         14 . A pharmaceutical composition comprising the  Pelargonium graveolens  constituents according to  claim 8 . 
     
     
         15 . A pharmaceutical composition comprising the  Pelargonium graveolens  constituents according to  claim 8 , wherein said composition in the form of drug, food, medicinal food, food additive or beverage. 
     
     
         16 .  Pelargonium graveolens  for use in treating a neurodegenerative condition selected from the group consisting of Parkinson's disease, parkinsonian dementia (PDem), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), anorexia nervosa, traumatic brain injury (TBI), and Parkinson's disease falling short of dementia (CIND-PD). 
     
     
         17 .  Pelargonium graveolens  according to  claim 16  for use in treating Parkinson's disease. 
     
     
         18 .  Pelargonium graveolens  according to  claim 16 , wherein said  Pelargonium graveolens  is the sole active ingredient. 
     
     
         19 . Use of  Pelargonium graveolens  in the preparation of a medicament for treating a neurodegenerative condition selected from the group consisting of Parkinson's disease, parkinsonian dementia (PDem), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), anorexia nervosa, traumatic brain injury (TBI), and Parkinson's disease falling short of dementia (CIND-PD). 
     
     
         20 . A pharmaceutical composition comprising  Pelargonium graveolens  for use in treating a neurodegenerative condition selected from the group consisting of Parkinson's disease, parkinsonian dementia (PDem), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), anorexia nervosa, traumatic brain injury (TBI), and Parkinson's disease falling short of dementia (CIND-PD). 
     
     
         21 . A pharmaceutical composition comprising  Pelargonium graveolens  for use in treating Parkinson's disease. 
     
     
         22 . A pharmaceutical composition comprising  Pelargonium graveolens  for use in preventing death of dopaminergic neurons. 
     
     
         23 . The use according to  claim 5 , wherein the  Pelargonium graveolens  constituents are in the form of essential oil. 
     
     
         24 . The use according  claim 5 , wherein said neurodegenerative condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, parkinsonian dementia (PDem), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), anorexia nervosa, traumatic brain injury (TBI), and Parkinson's disease falling short of dementia (CIND-PD). 
     
     
         25 . The  Pelargonium graveolens  constituents according to  claim 12 , wherein said neurodegenerative condition is selected from the group consisting of Parkinson's disease, parkinsonian dementia (PDem), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), anorexia nervosa, traumatic brain injury (TBI), and Parkinson's disease falling short of dementia (CIND-PD). 
     
     
         26 .  Pelargonium graveolens  according to  claim 17 , wherein said  Pelargonium graveolens  is the sole active ingredient.

Join the waitlist — get patent alerts

Track US2015320700A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.